Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review
Abstract
:1. Introduction and Clinical Significance
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Marcellinaro, R.; Spoletini, D.; Grieco, M.; Avella, P.; Cappuccio, M.; Troiano, R.; Lisi, G.; Garbarino, G.M.; Carlini, M. Colorectal Cancer: Current Updates and Future Perspectives. J. Clin. Med. 2023, 13, 40. [Google Scholar] [CrossRef]
- Zhang, Y.; Zhang, F.; Zhao, L.; Fu, X.; Shang, Y.; Gao, Q. Long-term survival of a patient with microsatellite-stable refractory colorectal cancer with regorafenib and PD-1 inhibitor sintilimab: A case report and review of literature. BMC Gastroenterol. 2021, 21, 399. [Google Scholar] [CrossRef] [PubMed]
- Kunst, N.; Alarid-Escudero, F.; Aas, E.; Coupé, V.M.; Schrag, D.; Kuntz, K.M. Estimating population-based recurrence rates of colorectal cancer over time in the United States. Cancer Epidemiol. Biomark. Prev. 2020, 29, 2710–2718. [Google Scholar] [CrossRef] [PubMed]
- Cho, S.M.; Esmail, A.; Abdelrahim, M. Triple-Regimen of Vemurafenib, Irinotecan, and Cetuximab for the Treatment of BRAFV600E-Mutant.CRC: A Case Report and Review. Front. Pharmacol. 2021, 12, 795381. [Google Scholar] [CrossRef]
- Schuell, B.; Gruenberger, T.; Kornek, G.; Dworan, N.; Depisch, D.; Lang, F.; Schneeweiss, B.; Scheithauer, W. Side effects during chemotherapy predict tumour response in advanced colorectal cancer. Br. J. Cancer 2005, 93, 744–748. [Google Scholar] [CrossRef]
- Zhou, J.; Ji, Q.; Li, Q. Resistance to anti-EGFR therapies in metastatic colorectal cancer: Underlying mechanisms and reversal strategies. J. Exp. Clin. Cancer Res. 2021, 40, 328. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef]
- Grothey, A.; Van Cutsem, E.; Sobrero, A.; Siena, S.; Falcone, A.; Ychou, M.; Humblet, Y.; Bouché, O.; Mineur, L.; Barone, C.; et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013, 381, 303–312. [Google Scholar] [CrossRef]
- Li, J.; Qin, S.; Xu, R.; Yau, T.C.; Ma, B.; Pan, H.; Xu, J.; Bai, Y.; Chi, Y.; Wang, L.; et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015, 16, 619–629. [Google Scholar] [CrossRef]
- Prager, G.W.; Taieb, J.; Fakih, M.; Ciardiello, F.; Cutsem, E.V.; Elez, E.; Cruz, F.M.; Wyrwicz, L.; Stroyakovskiy, D.; Pápai, Z.; et al. Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N. Engl. J. Med. 2023, 388, 1657–1667. [Google Scholar] [CrossRef]
- FDA approves regorafenib (Stivarga) for metastatic colorectal cancer. Oncology 2012, 26, 896. [PubMed]
- Fondevila, F.; Méndez-Blanco, C.; Fernández-Palanca, P.; González-Gallego, J.; Mauriz, J.L. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp. Mol. Med. 2019, 51, 1–15. [Google Scholar] [CrossRef]
- Wilhelm, S.M.; Dumas, J.; Adnane, L.; Lynch, M.; Carter, C.A.; Schütz, G.; Thierauch, K.H.; Zopf, D. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 2011, 129, 245–255. [Google Scholar] [CrossRef] [PubMed]
- Abou-Elkacem, L.; Arns, S.; Brix, G.; Gremse, F.; Zopf, D.; Kiessling, F.; Lederle, W. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol. Cancer Ther. 2013, 12, 1322–1331. [Google Scholar] [CrossRef]
- Van Cutsem, E.; Martinelli, E.; Cascinu, S.; Sobrero, A.; Banzi, M.; Seitz, J.F.; Barone, C.; Ychou, M.; Peeters, M.; Brenner, B. Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: Results of the large, single-arm, open-label phase IIIb CONSIGN study. Oncology 2019, 24, 185–192. [Google Scholar] [CrossRef]
- Prince, G.T.; Cameron, M.C.; Fathi, R.; Alkousakis, T. Topical 5-fluorouracil in dermatologic disease. Int. J. Dermatol. 2018, 57, 1259–1264. [Google Scholar] [CrossRef] [PubMed]
- Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer 2003, 3, 330–338. [Google Scholar] [CrossRef]
- Afzal, S.; Jensen, S.; Vainer, B.; Vogel, U.; Matsen, J.; Sørensen, J.; Andersen, P.K.; Poulsen, H. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann. Oncol. 2009, 20, 1660–1666. [Google Scholar] [CrossRef]
- Canman, C.E.; Tang, H.-Y.; Normolle, D.P.; Lawrence, T.S.; Maybaum, J. Variations in patterns of DNA damage induced in human colorectal tumor cells by 5-fluorodeoxyuridine: Implications for mechanisms of resistance and cytotoxicity. Proc. Natl. Acad. Sci. USA 1992, 89, 10474–10478. [Google Scholar] [CrossRef]
- de Gramont, A.; Figer, A.; Seymour, M.; Homerin, M.; Hmissi, A.; Cassidy, J.; Boni, C.; Cortes-Funes, H.; Cervantes, A.; Freyer, G. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 2000, 18, 2938–2947. [Google Scholar] [CrossRef]
- Zhao, J.; Li, W.; Zhu, D.; Yu, Q.; Zhang, Z.; Sun, M.; Cai, S.; Zhang, W. Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Med. Oncol. 2014, 31, 802. [Google Scholar] [CrossRef] [PubMed]
- Marks, E.I.; Tan, C.; Zhang, J.; Zhou, L.; Yang, Z.; Scicchitano, A.; El-Deiry, W.S. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biol. Ther. 2015, 16, 1710–1719. [Google Scholar] [CrossRef] [PubMed]
- Cai, M.-H.; Xu, X.-G.; Yan, S.-L.; Sun, Z.; Ying, Y.; Wang, B.-K.; Tu, Y.-X. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling. J. Exp. Clin. Cancer Res. 2018, 37, 151. [Google Scholar] [CrossRef] [PubMed]
- Baik, H.; Lee, H.J.; Park, J.; Park, H.Y.; Park, J.; Lee, S.; Bae, K.B. Complete response of MSI-high metastatic colon cancer following treatment with regorafenib: A case report. Mol. Clin. Oncol. 2021, 15, 243. [Google Scholar] [CrossRef]
- Calcagno, F.; Lenoble, S.; Lakkis, Z.; Nguyen, T.; Limat, S.; Borg, C.; Jary, M.; Kim, S.; Nerich, V. Efficacy, safety and cost of regorafenib in patients with metastatic colorectal cancer in French clinical practice. Clin. Med. Insights Oncol. 2016, 10, CMO–S38335. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Esmail, A.; Khasawneh, B.; Al-Najjar, E.; Zaidan, R.; Abdelrahim, M. Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review. Reports 2025, 8, 59. https://doi.org/10.3390/reports8020059
Esmail A, Khasawneh B, Al-Najjar E, Zaidan R, Abdelrahim M. Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review. Reports. 2025; 8(2):59. https://doi.org/10.3390/reports8020059
Chicago/Turabian StyleEsmail, Abdullah, Bayan Khasawneh, Ebtesam Al-Najjar, Raed Zaidan, and Maen Abdelrahim. 2025. "Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review" Reports 8, no. 2: 59. https://doi.org/10.3390/reports8020059
APA StyleEsmail, A., Khasawneh, B., Al-Najjar, E., Zaidan, R., & Abdelrahim, M. (2025). Prolonged Survival Outcome in a Patient with Refractory Metastatic Colorectal Cancer Treated with Regorafenib Plus 5-Fluorouracil: A Case Report and Literature Review. Reports, 8(2), 59. https://doi.org/10.3390/reports8020059